Join to access to all OVN content. Join for Free
Why Companies Should Hire Aspiring MSLs (and How)
MSL role Medical Science Liaison aspiring MSLs networking in medical affairs diversity hiring in pharmaceuticals

Why Companies Should Hire Aspiring MSLs (and How)


Share This Article


Summary

In this episode, Alyson Evans joins Tom Caravela to discuss the evolving landscape of the MSL role. Alyson shares her career journey and offers insights on hiring practices, comparing the strengths of aspiring versus experienced MSLs. She provides comprehensive advice for those looking to break into the field, highlighting the importance of networking and purposeful diversity in hiring. Alyson also predicts future trends that could shape the MSL role. The episode wraps up with final thoughts and actionable advice for aspiring MSLs, encouraging listeners to remain proactive and engaged in their career development.

My guest today is Alyson Evans, Director, Medical Affairs with Sirtex Pharmaceuticals. Alyson discusses why companies should consider hiring aspiring MSLs.

She shares…

πŸ‘‰ Why she considers hiring aspiring MSLs and what her experience has been
πŸ‘‰ The advantages and disadvantages of hiring aspiring MSLs
πŸ‘‰ How to go about hiring aspiring MSLs
πŸ‘‰ What “purposeful diversity hiring” is
πŸ‘‰ What advice she has for aspiring MSLs looking to land a role as a Medical Science Liaison

Click for Source
MSL role, Medical Science Liaison, aspiring MSLs, networking in medical affairs, diversity hiring in pharmaceuticals

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, GaΓ«lle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Explore OVN